Myocardial ischemia: A silent epidemic in Type 2 diabetes patients

Future Cardiology

Volumn 7, Issue 2, 2011, Pages 183-190

  Le Feuvre, Claude ^a   Jacqueminet, Sophie ^a   Barthelemy, Olivier ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

coronary artery disease; diabetes mellitus; silent myocardial ischemia

Indexed keywords

ANGIOCARDIOGRAPHY; BARE METAL STENT; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ELECTROCARDIOGRAPHY; EPIDEMIC; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SCREENING; SILENT MYOCARDIAL ISCHEMIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY;

DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; MYOCARDIAL ISCHEMIA; PREVALENCE; WORLD HEALTH;

EID: 79953750675     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.127     Document Type: Review

References (42)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
2. Cowie CC, Rust KF, Ford ES et al.: Full accounting of diabetes and prediabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care 32, 287-294 (2009).
3. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ: Impact of recent increase in incidence on future diabetes burden: US, 2005-2050. Diabetes Care 29, 2114-2116 (2006).
4. Cohn PF: Should silent ischemia be treated in asymptomatic individuals? Circulation 82(Suppl. II), 149-154 (1990).
5. Puel J, Valensi P, Vanzetto G et al.: Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. Diabetes Metab. 30(3 Pt 3), S3-S18 (2004).
6. American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February (1998), Miami, Florida. Diabetes Care 21, 1551-1559 (1998).
7. Diamond GA, Kaul S, Shah PK: Screen testing cardiovascular prevention in asymptomatic diabetic patients. J. Am. Coll. Cardiol. 1549, 1915-1917 (2007).
8. Hiebel A, Fagot-Campagna A, Fosse S, Varroud-Vidal M, Weill A, Penfornis A: Feasibility of screening for silent myocardial ischemia according to the ALFEDIAM-SFC 2004 guidelines in a population of diabetic patients. Diabetes Metab. 36, 286-292 (2010).
9. Shirani J, Dilsizian V: Screening asymptomatic patients with Type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome? Curr. Cardiol. Rep. 12, 140-146 (2010).
10. The BARI 2D study group: A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503-2515 (2009).
11. Henderson RA, Pocock SJ, Clayton TC et al.: Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J. Am. Coll. Cardiol. 142, 1161-1170 (2003).
12. Hueb W, Lopes NH, Gersh BJ et al.: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115, 1082-1089 (2007).
13. Boden WE, O'Rourke RA, Teo KK et al.: COURAGE Trial Research Group: optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007).
14. Hakeem A, Bhatti S, Karmali KN et al.: Renal function and risk stratification of diabetic and non diabetic patients undergoing evaluation for coronary artery disease. JACC Cardiovasc. Imaging 7, 734-745 (2010).
15. Kamalesh M, Shen J: Diabetes and peripheral arterial disease in men: trends in prevalence, mortality, and effect of concomitant coronary disease. Clin. Cardiol. 32, 442-446 (2009).
16. Grundy SM, Benjamin IJ, Burke GL et al.: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146 (1999).
17. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J. Am. Coll. Cardiol. 35(5), 1122-1129 (2000).
18. Koïstinen MJ: Prevalence of asymptomatic myocardial ischemia in diabetic subjects. Br. Med. J. 301, 92-95 (1990).
19. Milan Study on Atherosclerosis and Diabetes (MiSAD) group: Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am. J. Cardiol. 79, 134-139 (1997).
20. Vanzetto G, Halimi S, Hammoud T et al.: Prediction of cardio-vascular events in clinically selected high-risk NIDDM patients. Diabetes Care 22, 19-26 (1999).
21. Valensi P, Paries J, Brulport-Cerisier V et al.: Predictive value of silent myocardial ischemia for cadiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 11, 2722-2727 (2005).
22. Kip KE, Faxon DP, Detre KM et al.; The NHLBI Registry. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 94, 1818-1825 (1996).
23. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008).
24. Rogers WJ, Bourassa MG, Andrews TC et al.: Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J. Am. Coll. Cardiol. (3), 594-605 (1995).
25. Fox KM: European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362(9386), 782-788 (2003).
26. Yusuf S, Zucker D, Peduzzi P et al.: Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344(8922), 563-570 (1994). Erratum in: Lancet 344(8934), 1446 (1994).
27. Morice MC, Serruys PW, Kappetein AP et al.: Outcomes in patients with de novo left main disease treated with either PCI using paclitaxel-eluting stents or CABG treatment in the SYNTAX trial. Circulation 24, 2645-2653 (2010).
28. Ferro A, Pellegrino T, Spinelli L, Acampa W, Petretta M, Cuocolo A: Comparison between dobutamine echocardiography and SPECT for interpretive reproductibility. Am. J. Cardiol. 100, 1239-1244 (2007).
29. Acampa W, Spinelli L, Petretta M, De Lauro F, Ibello F, Cuocolo A: Prognostic value of myocardial ischemia in patients with uncomplicated AMI: direct comparison of stress echocardiography and myocardial perfusion imaging. J. Nucl. Med. 46, 417-423 (2005).
30. Le Feuvre C, Barthélémy O, Dubois-Laforgue D et al.: Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with Type 2 diabetes. Diabetes Metab. 31, 135-142 (2005).
31. Jacqueminet S, Barthelemy O, Le Feuvre C: Screening of silent myocardial ischemia in Type 2 diabetic patients. Diabetes Care 33, 79 (2010).
32. Barthelemy O, Jacqueminet S, Rouzet F et al.: Intensive care of cardiovascular risk factors and prevalence of silent myocardial ischemia in Type 2 diabetic patients. Arch. Cardiovasc. Dis. 101, 539-547 (2008).
33. Young LH, Wackers FJ, Chyun DA et al.: Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with Type 2 diabetes. The DIAD study: a randomized controlled trial. JAMA 301, 1547-1555 (2009).
34. Valensi P, Sachs RN, Lormeau B et al.: Silent myocardial ischemia and left ventricle hypertrophy in diabetic patients. Diabetes Metab. 23, 409-416 (1997).
35. Jannand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V: Silent myocardial ischemia in patients with diabetes. Diabetes Care 22, 1396-1400 (1999).
36. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR: Impairment of coronary vascular reserve and Ach-induced coronary vasodialtion in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42, 1017-1025 (1993).
37. Conroy RM, Piörälä K, Fitzgerald AP et al.: Estimation of ten-years risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur. Heart J. 24, 897-1003 (2003).
38. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 285, 2487-2497 (2001).
39. Chobanian AV, Bakris GL, Black HR et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003) Erratum in: JAMA 290(2), 197 (2003).
40. Schouten O, van Kuijk JP, Flu WJ et al.: Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery. Am. J. Cardiol. 103, 897-901 (2009).
41. Faglia E, Manuela M, Antonella Q et al.: Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with Type 2 diabets mellitus at high cardiovascular risk: an open-label randomized pilot study. Am. Heart J. 149, e1-e6 (2005).
42. Medical treatment in Type 2 diabetic patients. Professional recommendations. HAS (2006) www.has-sante.fr